Compare NC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | PROK |
|---|---|---|
| Founded | 1913 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.1M | 331.2M |
| IPO Year | 2006 | 2021 |
| Metric | NC | PROK |
|---|---|---|
| Price | $51.12 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 11.5K | ★ 576.0K |
| Earning Date | 03-04-2026 | 03-18-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.35 | N/A |
| Revenue | ★ $104,778,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $20.77 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $30.00 | $0.46 |
| 52 Week High | $59.42 | $7.13 |
| Indicator | NC | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 39.86 |
| Support Level | $45.41 | $1.71 |
| Resistance Level | $55.09 | $2.58 |
| Average True Range (ATR) | 2.76 | 0.16 |
| MACD | -0.46 | -0.05 |
| Stochastic Oscillator | 31.68 | 15.97 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.